Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perry, E.
Right arrow Articles by Ballard, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perry, E.
Right arrow Articles by Ballard, C.
Related Collections
Right arrow All Cognitive Disorders/Dementia
Right arrow Alzheimer's disease
Right arrow Dementia with Lewy bodies
Right arrow Assessment of cognitive disorders/dementia

Neurology 2003;60:1852-1853
© 2003 American Academy of Neurology
Brief Communications

Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies

Elaine Perry, PhD, Ian McKeith, FRCPsych and Clive Ballard, MRCPsych

From the Institute for Ageing and Health, Newcastle, UK.

Address correspondence and reprint requests to Professor E.K. Perry, Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE UK; e-mail: e.k.perry{at}ncl.ac.uk

Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
N. H. Greig, T. Utsuki, D. K. Ingram, Y. Wang, G. Pepeu, C. Scali, Q.-S. Yu, J. Mamczarz, H. W. Holloway, T. Giordano, et al.
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer {beta}-amyloid peptide in rodent
PNAS, November 22, 2005; 102(47): 17213 - 17218.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
J. M. Ellis
Cholinesterase Inhibitors in the Treatment of Dementia
J Am Osteopath Assoc, March 1, 2005; 105(3): 145 - 158.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Roivainen, J. Rinne, J. Virta, T. Jarvenpaa, S. Salomaki, M. Yu, and K. Nagren
Biodistribution and Blood Metabolism of 1-11C-Methyl-4-Piperidinyl n-Butyrate in Humans: An Imaging Agent for In Vivo Assessment of Butyrylcholinesterase Activity with PET
J. Nucl. Med., December 1, 2004; 45(12): 2032 - 2039.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
D. Aarsland, U. P. Mosimann, and I. G. McKeith
Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies
J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 164 - 171.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.